Cargando…
Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients
Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society of Cardiology
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711674/ https://www.ncbi.nlm.nih.gov/pubmed/29171208 http://dx.doi.org/10.4070/kcj.2017.0158 |